Sybron Dental Specialties, Inc. Announces the Mailing of its Offer to Purchase All of the Outstanding Common Shares of Innova LifeSciences Corporation TORONTO, Sept. 9 /PRNewswire/ -- Sybron Dental Specialties, Inc. ("Sybron") and Innova LifeSciences Corporation ("Innova") jointly announced today that Sybron has mailed to shareholders of Innova the offer and circular dated September 8, 2004 (the "Circular") and related documents, in connection with the previously announced offer (the "Offer") being made through its indirect wholly-owned subsidiary, Sybron Canada Limited, to purchase all of the outstanding common shares of Innova. Included in the package mailed to shareholders was the Directors' Circular prepared by Innova's board of directors recommending that Innova shareholders accept the Offer. Pursuant to the Offer, Sybron is offering to purchase all of the issued and outstanding common shares of Innova, including common shares which may become outstanding on the exercise of options, warrants or other rights to purchase common shares, at a price of $1.4106 in cash per common share. The purchase price payable under the Offer represents a 33% premium over the closing price of Innova's common shares on August 23, 2004, the last trading day prior to the announcement of the Offer, and a 37% premium over the volume weighted average price of the common shares on the Toronto Stock Exchange for the 20-day trading period ending on that date. The Offer is subject to certain conditions, including there being validly deposited under the Offer, at the expiry of the Offer, at least 66 .% of the issued and outstanding common shares of Innova (on a fully diluted basis). The VenGrowth Investment Fund Inc., The VenGrowth II Investment Fund Inc., The Manufacturers Life Insurance Company, Michael A. Kehoe, the President and Chief Executive Officer of Innova, and Keith L. Carter, the Vice-President and Secretary of Innova, which together hold approximately 62.1% of the outstanding common shares (approximately 57.3% on a fully-diluted basis) have entered into an agreement with Sybron to tender their common shares to the Offer. The Offer expires at 12:01 a.m. on October 15, 2004. About Innova LifeSciences Innova (http://www.innovalife.com/) specializes in the development, manufacture and global marketing of proprietary medical devices and technologies, and is committed to continued profitable growth by advancing its technology, enriching its value proposition for customers and adding innovative complementary technologies. Endopore, Innova's brand name dental implant system, is now used by dental professionals in more than 20 countries as a preferred technology to anchor dental prostheses such as dentures, partial plates, bridgework and single teeth. A Canadian company, Innova was founded in 1988 and its technologies are approved by a wide range of health authorities, including the United States Food and Drug Administration. About Sybron Dental Specialties Sybron Dental Specialties (http://www.sybrondental.com/) and its subsidiaries are leading manufacturers of value-added products for the dental and orthodontic professions and products for use in infection control. Sybron Dental Specialties develops, manufactures, and sells through independent distributors a comprehensive line of consumable general dental and infection prevention products to the dental industry worldwide. It also develops, manufactures, markets and distributes an array of consumable orthodontic and endodontic products worldwide. DATASOURCE: Sybron Dental Specialties, Inc. CONTACT: Gregory D. Waller, Chief Financial Officer - Sybron, +1-714-516-7400; or Michael Nealon, Chief Financial Officer - Innova, +1-416-340-8818 Web site: http://www.sybrondental.com/

Copyright